Navigation Links
Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma
Date:6/4/2008

Results of phase I/II study highlighted in oral presentation at conference

on malignant lymphoma

LUGANO, Switzerland, June 5 /PRNewswire-FirstCall/ -- At the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland data were presented from a phase I/II investigator-sponsored clinical trial of Yttrium-90 Ibritumomab Tiuxetan (90Y-Zevalin) combined with the novel expanded porphyrin motexafin gadolinium (MGd). The greatest benefit of this investigational regimen was observed in rituximab-refractory follicular lymphoma patients, who experienced rapid responses and a high rate of durable complete responses (CR). In this subset of patients (n=14), 64 percent experienced a complete response with a median estimated time to progression (TTP) of 14 months. These results compare favorably to prior published data of single agent Zevalin in terms of CR and TTP. The investigators concluded that MGd given with Zevalin does not appear to increase hematologic or other toxicities. Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) markets Zevalin in the United States. MGd is under development by Pharmacyclics, Inc.

"Zevalin is approved for relapsed follicular non-Hodgkin's lymphoma based on superior overall and complete response rates compared to rituximab, including rituximab-refractory follicular non-Hodgkin's lymphoma where Zevalin resulted in a 74 percent overall response rate with 15 percent complete and unconfirmed complete responses," said James A. Bianco, M.D., President and CEO of CTI. "The results of the study suggest that addition of MGd may enhance the effectiveness of radioimmunotherapy with Zevalin. Further studies using this combination in patients with follicular or diffuse large B-cell lymphoma are warranted."

About the Study

Of the 30 patients enrolled on this study, 28 are currently evaluable. All patients were rituximab-refractory. No dose limiting toxicity was seen. No grade 4 non-he
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Novel Technology Breaks Through Cancer Pain
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
4. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
5. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
6. NIST team develops novel method for nanostructured polymer thin films
7. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
8. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
9. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
10. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
11. GenVault and the National Center for Forensic Science to Present Novel Technology for Room Temperature Storage of RNA

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...YandBLENHEIM,Ontario,Nov.24/PRNewswire-FirstCall/-...heassetsofHylandSeeds,adivisionofThompsonsLimitedo...herexpandDowAgroSciences,currentseedsbusinessasthe...in 2010 andDowAgroSciencesHerbicideTolerantTrait...ctedinthenearfuture. ,, "Thisacquisitionbringst...
(Date:11/24/2009)...VIK,Iceland,November24/PRNewswire-FirstCall/--deCO...provalofallofits,"firstday"motionsbytheU.S.Bankrup...urt").deCODElastweekfiledavoluntarypetitionfor,rel...ththe,BankruptcyCourt. , Theordersissuedbythe...itsbusinessduringtheChapter11proceedings.Inparticu...
(Date:11/24/2009)...E,Nov.24/PRNewswire/--BlueMarbleEnergyCorp.announc...Authority(OPDA)wererecentlyawarded$2millionbyWashi...ERB)inaprivate/publicpartnershiptoconstructthestat...unty,WA. ,, "Thisinvestmentwillsignificantlyspe...njobstoLincolnCounty,"saidBlueMarbleEnergyCEOKelly...
(Date:11/24/2009)...,November24/PRNewswire-FirstCall/--Shireplc(LSE:SH...icalcompany,today,announcedthatithassubmittedaMAAt...hecompany,senzymereplacementtherapyindevelopment,f...marketing,applicationforvelaglucerasealfathathasbe...tesandCanada. , Basedonaglobalsupplyshortageo...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3
...linical Pharmacokinetic Data to be Presented at th...n Uveitis in Germany, ZURICH, Switzerland, Sept. ...agment therapeutics, today announced that the,comp...l study of the,company,s lead product candidate, E...ESBATech initiated the Phase I study designed to e...
...ese funds will be used to rapidly implement the f...ctivity expansion in order to meet strongly inc...t raising additional capital now-, - The Company ...ent of the previously announced convertible deb...uebec, Sept. 8 /PRNewswire-FirstCall/ - Neptune Te...
...TLE, Sept. 6 Cell Therapeutics, Inc.,(CTI) (Nasda...he Company,received a letter from the Listing Qual...dicating that the Company is not in compliance wit...ecurities requirement set forth,in NASDAQ Marketpl...oes not,comply with NASDAQ Marketplace Rule 4450(b...
Other Biology Technology:ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group 2Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group 3CTI Receives NASDAQ Letter 2CTI Receives NASDAQ Letter 3
(Date:11/25/2009)...refighters, police officers and ambulance workers ...e Center complex. They battled to save people from...s, tackled fires and evacuated as many people as t...17,000 people. And making their jobs even harder w...workers and their relatives jammed mobile networks...
(Date:11/25/2009)...you eat may be just as vital to your health as wha... for Biological Studies. Their experiments in mice...sands of genes in the liverthe body,s metabolic cl... not by the body,s circadian clock as conventional...he activity of a large number of genes completely ...
(Date:11/24/2009)...akened and flabby arteries from collapsing have be...tents are no longer needed -- once the arteries ar...y, doctors had no choice but to leave them in plac...ty,s Department of Biomedical Engineering has deve...ries drugs where they,re needed, then dissolves. ,...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3A coating for life 2New piece found in the puzzle of epigenetics 8855 1New piece found in the puzzle of epigenetics 8855 2Two Companies Expand in Ann Arbor Area With MEDC Support 49046 1Two Companies Expand in Ann Arbor Area With MEDC Support 49046 217 of Americas Most Promising Scientists Selected as 2009 Pew Scholars in the Biomedical Sciences 49041 117 of Americas Most Promising Scientists Selected as 2009 Pew Scholars in the Biomedical Sciences 49041 217 of Americas Most Promising Scientists Selected as 2009 Pew Scholars in the Biomedical Sciences 49041 317 of Americas Most Promising Scientists Selected as 2009 Pew Scholars in the Biomedical Sciences 49041 417 of Americas Most Promising Scientists Selected as 2009 Pew Scholars in the Biomedical Sciences 49041 5
...e fast disappearing from restaurant menus as stock... While the reasons for the eel decline remain as m...y a NOAA scientist and colleagues in Japan and the...nditions may be a primary factor in declining repr...ects of spawning and early life history of this sp...
...t of champions? That would be a soy protein-packed...ements for three different FDA health claims and l...at again until lunch. , University of Illinois sc...st such a cereal, one thats passed the taste test ...asons to eat soy--and even more reasons to consume...
...pleased to announce the launch of the Internationa...llows on the heels of the Panda Genome workshop he...Hongmei Zhu, a scientist from BGI-Shenzhen, stated...sequencing and assembling of the draft sequence wi...ved animal all over the world and is considered a ...
Other Biology News:Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 2Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 3U of I researcher develops power-packed soy breakfast cereal 2Giant panda genome to be sequenced 2Giant panda genome to be sequenced 3
Borrelia Burgdorferi-directed IgG EIA Kit from Alpco Diagnostics
96 Well Base Plate from ABgene
... is a protein ribonuclease inhibitor that noncoval...se A-type enzymes. No inhibition is seen with RNas...nct from human placental ribonuclease inhibitor in...and does not release active RNase in the absence o...
RNaseOUT Recombinant Ribonuclease Inhibitor from Invitrogen
Biology Products: